ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1386	National Cancer Institute	Html	en	Delirium (PDQ®)–Health Professional Version	Expert-reviewed information summary about delirium as a complication of cancer or its treatment. Supportive care and pharmacologic approaches to the management of delirium are discussed.	elderly patients 0.428132 palliative medicine 0.41962 Fainsinger RL 0.451294 cancer center 0.422328 parent opioid compound 0.416673 palliative sedation. 0.469946 terminal sedation 0.549416 advanced cancer patients 0.459954 health care personnel 0.42512 QTc prolongation 0.496258 intravenous haloperidol 0.415462 risk factors 0.405793 refractory delirium 0.559163 oral opioid doses 0.440498 patients 0.718812 cancer patients 0.560957 sedation management. 0.490138 Lawlor PG 0.441422 palliative sedation therapy 0.708844 hypoactive delirium 0.522797 Palliat Care 0.456046 Pain Symptom Manage 0.718675 deep palliative sedation 0.612386 et al. 0.454631 study 0.418964	opioid toxicity 0.40801 deep sedation 0.500093 palliative care 0.916963 PUBMED Abstract 0.605152 agitated delirium 0.529672 haloperidol 0.510465 Opioid rotation section 0.412964 Support Care Cancer 0.588217 terminally ill patients 0.594369 delirium 0.992491 palliative sedation 0.977292 palliative care support 0.490339 Delirium reversal 0.553183 advanced cancer 0.474165 acute palliative care 0.478818 palliative care patients 0.570294 Palliat Med 0.428812 ill cancer patients 0.443961 palliative care experience 0.501267 palliative care unit 0.618846 palliative care units 0.586545 versus continuous sedation 0.526162 Injectable haloperidol 0.422082 palliative care programs 0.565085	CLICK HERE
1421	National Cancer Institute	Html	en	Gastrointestinal Complications (PDQ®)–Patient Version	Expert-reviewed information summary about constipation, impaction, bowel obstruction, and diarrhea as complications of cancer or its treatment. The management of these problems is discussed.	red blood cells 0.59878 stool 0.665289 cancer treatment 0.386923 acute enteritis 0.365068 general signs 0.397049 Fecal occult blood 0.425816 bowel movements 0.59883 body 0.382296 PDQ cancer information 0.480572 low blood pressure 0.378182 Acute bowel obstructions 0.360846 white blood cells 0.495045 normal bowel function 0.348728 Digital rectal exam 0.477206 radiation enteritis 0.451513 clinical trials 0.412365 bowel movement 0.9808 cancer information summary 0.416977 constipation 0.510652 clinical trial 0.351928 blood pressure 0.387153 patients 0.595376 cancer patients 0.514161 diarrhea 0.490455 dry stool 0.353386	symptoms 0.370324 watery bowel movements 0.352417 NCI PDQ cancer 0.351977 radiation therapy 0.58958 occult blood test 0.398605 rectum 0.509438 small intestine 0.391741 fecal impaction 0.927514 stool softeners 0.403803 treatment 0.634263 medicines 0.37024 bowel obstructions 0.392819 abdomen 0.481971 bowel obstruction 0.468528 National Cancer Institute 0.437526 Cancer Care 0.355451 energy beam 0.402215 acute radiation enteritis 0.392407 GI complications 0.360144 PDQ summary 0.394667 doctor 0.384993 bowel sounds 0.369971 cancer 0.734003 large intestine 0.487328	CLICK HERE
1497	National Cancer Institute	Html	en	Myelodysplastic Syndromes Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of myelodysplastic syndromes (MDS).	myeloid growth factors 0.477206 granulocyte colony-stimulating factor 0.557441 FDA-approved azacitidine dose 0.443901 high transfusion needs. 0.434847 higher-risk myelodysplastic syndrome 0.514853 phase II study 0.511019 high erythropoietin level 0.498344 randomized phase 0.474562 growth factors 0.484307 pretreatment serum erythropoietin 0.492675 patients 0.775734 MDS patients 0.554625 intermediate-1 myelodysplasia patients 0.447201 hematologic response rates 0.432674 higher-risk patients 0.458735 refractory anemia 0.483028 myelodysplastic syndrome subtypes 0.506964 myelodysplastic syndromes 0.992723 higher-risk myelodysplastic syndromes 0.622445 et al. 0.55214 treatment 0.50898 lower-risk patients 0.438644 myelodysplastic syndrome results 0.533546 neutropenic MDS patients 0.534349 azacitidine congener decitabine 0.454696	disease progression 0.439916 Br J Haematol 0.475303 hematologic response 0.452427 phase III study 0.517603 high-risk myelodysplastic syndrome 0.555643 ongoing transfusion needs 0.425861 higher-risk MDS subtypes 0.450976 exogenous erythropoietin administration 0.49424 substantial transfusion history 0.426145 major erythroid response 0.428669 endogenous erythropoietin level 0.504489 febrile patients 0.431259 Abstract 0.587934 transfusion independence 0.490752 serum erythropoietin level 0.660226 Clin Oncol 0.63272 MDS Study Group 0.445503 response rates 0.442209 low serum erythropoietin 0.484277 prophylactic platelet transfusions 0.42316 blood 0.443517 transfusion-dependent MDS patients 0.515881 response 0.499354 lower-risk myelodysplastic syndromes 0.547199	CLICK HERE
1552	National Cancer Institute	Html	en	Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Patient Version	Childhood ALL is a type of cancer in which the bone marrow makes too many immature lymphocytes (a type of white blood cell). Here’s what you need to know about the risk factors, signs, tests to diagnose, and treatment of newly diagnosed and recurrent ALL in this expert-reviewed summary.	red blood cells 0.416225 cancer treatment 0.28631 chemotherapy 0.431874 treatments 0.247489 PDQ cancer information 0.278302 clinical trial search 0.311111 white blood cells 0.50903 children 0.34365 systemic chemotherapy 0.367092 higher doses 0.258659 mature blood cells 0.277223 Natural killer cells 0.232346 cancer information summary 0.242631 clinical trial 0.414978 stem cells 0.325781 stem cell transplant 0.490178 Lymphoblastic Leukemia Treatment 0.242048 blood cells 0.556083 intrathecal chemotherapy 0.289545 radiation therapy 0.442509 General information 0.218828 child 0.225345 treatment 0.73359 immature blood cells 0.228445 NCI-supported cancer 0.228604	cancer cells 0.364563 remission induction 0.378898 anticancer drugs 0.454791 specific cancer cells 0.244448 acute lymphocytic leukemia 0.228943 certain changes 0.25566 treatment clinical trials 0.245143 blood stem cells 0.262182 National Cancer Institute 0.245665 spinal cord 0.639894 ) cells. 0.915202 new treatment 0.267478 consolidation /intensification 0.293759 childhood 0.307766 clinical trials 0.932686 combination chemotherapy 0.358378 maintenance phases 0.246634 brain 0.275475 bone marrow 0.619374 Philadelphia chromosome 0.248781 cancer clinical trials 0.319159 acute lymphoblastic leukemia 0.930995 cancer 0.710977 information 0.309067	CLICK HERE
1651	National Cancer Institute	Html	en	Milk Thistle (PDQ®)–Patient Version	Expert-reviewed information summary about the use of milk thistle as a treatment for people with cancer.	cancer treatment 0.701214 advanced liver cancer 0.66555 PDQ cancer information 0.729457 Cancer Complementary 0.666923 clinical trials 0.798052 U.S. Food 0.649163 cancer information summary 0.699946 alternative cancer therapies 0.663524 clinical trial 0.731299 CAM cancer research 0.657056 patients 0.673877 cancer patients 0.654835 randomized clinical trial 0.683387 Marian thistle 0.690666 NCI PDQ cancer 0.677418 cancer information database 0.662437 radiation therapy 0.660512 Therapies Editorial Board 0.664492 cancer information 0.734643 treatment 0.70795 cancer prevention 0.650452 Complementary Therapies Editorial 0.677699 United States 0.665688 Drug Administration 0.682045	Cancer Information Specialist 0.658528 cancer cells 0.669779 milk thistle supplements 0.741182 cancer cell lines 0.655527 anticancer medications 0.651405 Cancer Information Service 0.697895 CAM therapies 0.649867 treatment clinical trials 0.654645 National Cancer Institute 0.770559 alternative medicine 0.692591 conventional treatment 0.650077 St. Mary thistle 0.707197 Federal Trade Commission 0.651646 silymarin 0.670265 Cancer Care page 0.650369 breast cancer 0.668147 PDQ summary 0.650118 cancer clinical trials 0.667946 alternative therapies 0.674881 acute lymphoblastic leukemia 0.665296 neck cancer 0.65549 cancer information summaries 0.662842 colorectal cancer cells 0.652543 cancer 0.828322	CLICK HERE
1987	National Cancer Institute	Html	es	Tratamiento de los tumores embrionarios del sistema nervioso central infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del meduloblastoma infantil, los tumores embrionarios distintos del meduloblastoma y los tumores pineales infantiles.	sumario versa 0.501558 siguientes procedimientos 0.502311 células madre 0.524991 efectos secundarios meses 0.503043 siguientes aspectos 0.500523 años edad 0.500492 tratamiento mejora 0.501438 dosis pequeñas administras 0.501281 PDQ Descripción 0.501938 sección información 0.50094 efectos tardíos 0.505196 carcinoma nevoide 0.50085 PDQ Tumores 0.506016 PDQ Efectos tardíos 0.501814 líquido cefalorraquídeo 0.521206 punción espinal.Ampliar 0.500903 National Cancer Institute 0.5005 tumores benignos 0.508351 siguientes riesgos 0.500413 médula ósea.ampliar aspiración 0.502403 Instituto Nacional 0.501732	PDQ Tratamiento 0.505028 presente sumario 0.501062 determinados cambios 0.501002 riesgo promedio 0.513411 nuevos tipos 0.500625 riesgo alto.Riesgo promedio 0.501723 sistema nervioso central 0.814928 Physician Data Query 0.50178 brain tumor 0.501055 prueba irm 0.500762 Aboutâ„¢ Brain Tumors 0.500627 siguientes enfermedades 0.501038 cuánto tumor 0.503396 tumores embrionarios 0.994005 imágenes seguirán 0.500378 Cuánto tiempo 0.500383 siguientes enlaces 0.500476 SNC infantil recidivantes 0.502864 Brain Tumor Consortium 0.501941 infantil recidivantes 0.502523 siguientes pruebas 0.501153	CLICK HERE
2043	National Cancer Institute	Html	es	Prevención del cáncer de ovario, de trompas de Falopio y primario de peritoneo (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre los factores que influyen en el riesgo de presentar cáncer de ovario, de trompas de Falopio y primario de peritoneo y sobre las investigaciones dirigidas a la prevención de los mismos.	Obstet Gynecol 0.31235 oral contraceptives 0.309215 factores alimentarios 0.305635 histologic subtype 0.312055 Cancer Cohort Consortium 0.318833 Colorectal Cancer 0.308524 cancer risk factors 0.338538 An Analysis From 0.306638 Lacey JV Jr 0.313268 individual participant meta-analysis 0.306651 American Cancer Society 0.315301 Prospective Investigation into 0.306516 Ovarian Cancer Association 0.322566 Trabert B 0.318769 National Institutes 0.306184 Cancer Prev 0.318672 ovarian cancer 0.962228 bilateral oophorectomy 0.306539 population-based study 0.305827 Natl Cancer Inst 0.339156 múltiples estudios 0.32855 California Teachers Study 0.307709 Health Study Cohort 0.31028 hormone replacement therapy 0.312605 Beral V 0.305906	European Prospective Investigation 0.306439 investigation into cancer 0.318863 SEER Cancer Statistics 0.308163 Cancer Association Consortium 0.318478 cohort study 0.309167 prospectively studied cohort 0.307037 Midwifery Womens Health 0.306899 health study 0.334114 Cancer Facts 0.308362 tumores tipo 0.310257 National Cancer Institute 0.308306 ovarian cancer risk 0.650797 epidemiological studies 0.315154 antecedentes familiares 0.31063 nih-aarp diet 0.308944 carcinomas ováricos tipo 0.305728 Netherlands cohort study 0.308948 Gynecologic Cancers 0.321276 Yang HP 0.306882 Ovarian Cancer Cohort 0.322781 PDQ Genetics 0.322297 hormone-related risk factors 0.30545 Health-AARP Diet 0.307792 Women’s Health Initiative 0.307189	CLICK HERE
15647	National Cancer Institute	Html	en	Genomic Data Sharing (GDS) Policy Contact Information	Genomic Data Sharing Policy contact information, including NCI-Designated GPAs by division or center.	GPA assistant 0.93001 Cancer Training 0.249467 Shannon Hughes 0.229368 Sean Hanlon 0.257761 NIH GDS Policy 0.610914 Guidry Auvil Daniela 0.496929 NCI division 0.258673 Anil Wali Emmanuel 0.495613 Program Director 0.234183 Susan Perkins 0.231974 Cancer Genomics 0.271538	Claire Zhu 0.249716 Kathleen Calzone Anjan 0.535993 NCI-specific questions 0.235899 Cancer Epidemiology 0.243639 email GDS 0.354202 Cancer Health Disparities 0.465506 Natalia Abrams 0.263564 Cancer Research 0.254684 Cancer Prevention 0.23825 genomic program administrator 0.461255 Strategic Scientific Initiatives 0.388719	CLICK HERE
16833	National Cancer Institute	Html	en	News and Events	The latest news from the Office of Cancer Nanotechnology Research and the Alliance, as well as upcoming and past events attended by the Office of Cancer Nanotechnology Research staff, and relevant upcoming scientific meetings.	National Cancer Institute 0.924974		CLICK HERE
17170	National Cancer Institute	Html	es	PC-SPES (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Hsieh TC 0.512609 cell lines 0.580614 DiPaola RS 0.518041 herbal compound 0.512202 cell cycle arrest 0.510653 Panax ginseng 0.534566 androgen-dependent lncap cells 0.510949 herbal formulation 0.520455 próstata lncap 0.510141 herbal combination 0.538545 Cancer Res 0.532897 Cancer Prev 0.510115 PC-SPES which 0.510153 PSA Rising 0.510712 Estados Unidos 0.514599 Natl Cancer Inst 0.529649 Pirani JF 0.524938 LNCaP cells 0.518113 pc-spes contenía des 0.513216 patients with 0.561272 In vitro mechanism 0.515105 Taille A 0.52428 Scutellaria baicalensis 0.522111 prostate carcinoma 0.52183 panax ginseng c.a 0.528442	George DJ 0.512309 herbal compound pc-spes 0.515596 Oh WK 0.520298 Nutr Cancer 0.510533 Hayek OR 0.509996 Glycyrrhiza uralensis 0.513578 using pc-spes 0.518341 células lncap 0.515795 Serenoa repens 0.547922 Ganoderma lucidum 0.527517 PC-SPES demostró actividad 0.512446 cell cycle 0.533145 PC SPES 0.530969 herbal composition pc-spes 0.529409 Buttyan R 0.516728 vitro toxicity mediated 0.512005 recent clinical trials 0.523629 Prostate Cancer Survivor 0.513926 herbal therapy pc-spes 0.566579 herbal supplement pc-spes 0.555382 Chinese herbal 0.520945 prostate cancer 0.978435 datos probatorios 0.516673 in vitro 0.808088	CLICK HERE